I-Kuan Wang1,2,3, Cheng-Li Lin4,5, Hung-Chih Chen3, Shih-Yi Lin3, Chiz-Tzung Chang3, Tzung-Hai Yen6,7, Fung-Chang Sung4,8. 1. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. 2. Department of Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan. 3. Division of Kidney Disease, China Medical University Hospital, Taichung, Taiwan. 4. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 5. College of Medicine, China Medical University, Taichung, Taiwan. 6. Division of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan. 7. Chang Gung University College of Medicine, Taoyuan, Taiwan. 8. Department of Health Services Administration, China Medical University, Taichung, Taiwan.
Abstract
Background: This study compared the risk of developing new-onset diabetes between hemodialysis (HD) and peritoneal dialysis (PD) patients. We further investigated the effectiveness of icodextrin in reducing the risk of new-onset diabetes in PD patients. Methods: From the Taiwan health insurance database, 36 879 incident HD patients and 6382 incident PD patients from 2000 to 2010 were identified as study cohorts. We further selected an additional HD cohort matched by propensity scores (PSs) of PD patients. Incidence rates and hazard ratios (HRs) of new-onset diabetes were assessed among cohorts and between icodextrin users and nonusers by the end of 2011. Results: For the unmatched cohorts, the incidence of new-onset diabetes was higher in PD patients than in HD patients (9.16 versus 8.18 per 1000 person-years), with an adjusted HR of 1.51 (95% CI 1.30-1.75) for PD patients. For the PS-matched cohorts, the corresponding incidence rates were 9.43 and 5.90 per 1000 person-years, respectively, with an adjusted HR of 1.61 (95% CI 1.32-1.97). Among PD patients, the incidence was lower in icodextrin users than in nonusers (6.22 versus 12.1 per 1000 person-years), with an adjusted HR of 0.66 (95% CI 0.50-0.88) for users. Conclusions: Our study suggests that PD patients are at a higher risk of developing new-onset diabetes than HD patients. Icodextrin is recommended for PD patients to reduce the risk of new-onset diabetes.
Background: This study compared the risk of developing new-onset diabetes between hemodialysis (HD) and peritoneal dialysis (PD) patients. We further investigated the effectiveness of icodextrin in reducing the risk of new-onset diabetes in PDpatients. Methods: From the Taiwan health insurance database, 36 879 incident HDpatients and 6382 incident PDpatients from 2000 to 2010 were identified as study cohorts. We further selected an additional HD cohort matched by propensity scores (PSs) of PDpatients. Incidence rates and hazard ratios (HRs) of new-onset diabetes were assessed among cohorts and between icodextrin users and nonusers by the end of 2011. Results: For the unmatched cohorts, the incidence of new-onset diabetes was higher in PDpatients than in HDpatients (9.16 versus 8.18 per 1000 person-years), with an adjusted HR of 1.51 (95% CI 1.30-1.75) for PDpatients. For the PS-matched cohorts, the corresponding incidence rates were 9.43 and 5.90 per 1000 person-years, respectively, with an adjusted HR of 1.61 (95% CI 1.32-1.97). Among PDpatients, the incidence was lower in icodextrin users than in nonusers (6.22 versus 12.1 per 1000 person-years), with an adjusted HR of 0.66 (95% CI 0.50-0.88) for users. Conclusions: Our study suggests that PDpatients are at a higher risk of developing new-onset diabetes than HDpatients. Icodextrin is recommended for PDpatients to reduce the risk of new-onset diabetes.
Authors: Valentina Masola; Mario Bonomini; Silvio Borrelli; Lorenzo Di Liberato; Luigi Vecchi; Maurizio Onisto; Giovanni Gambaro; Roberto Palumbo; Arduino Arduini Journal: Int J Mol Sci Date: 2022-04-27 Impact factor: 6.208
Authors: Carmela Rago; Teresa Lombardi; Giorgia Di Fulvio; Lorenzo Di Liberato; Arduino Arduini; José C Divino-Filho; Mario Bonomini Journal: Toxins (Basel) Date: 2021-02-24 Impact factor: 4.546
Authors: Mario Bonomini; Francesc E Borras; Maribel Troya-Saborido; Laura Carreras-Planella; Lorenzo Di Liberato; Arduino Arduini Journal: Int J Mol Sci Date: 2020-07-31 Impact factor: 5.923